0001493152-26-022701
SEC filingQ1 revenue held steady at $2.2M despite Dental headwinds, while operating losses narrowed 59% to -$828K through disciplined cost management, driving first positive operating cash flow of $87K amid ongoing profitability challenges.
Revenue of $2.2 million represented a modest 3.2% decline from the prior year quarter, primarily reflecting lower sales volume in the Dental segment amid softer international distributor demand. This stability underscores the resilience of the core Wand Dental product line despite external pressures, while the Company advances its Medical segment commercialization.
Net income followed suit, narrowing 57.9% to a $840 thousand loss with diluted EPS of -$0.01 versus -$0.02. The Company has incurred recurring operating losses and carries an accumulated deficit, but this quarter's trajectory signals improved path to breakeven.
Management continues focusing on expanding adoption of its DPS technology platform, advancing Medical segment commercialization like the Compuflo Epidural System, and maintaining cost controls while pursuing targeted growth. A recent purchase order in April 2026 signals renewed market activity. Current cash resources, plus expected collections and financing, should support near-term operations, though the Company evaluates R&D investments for future product enhancements amid ongoing going concern considerations.